Karuna Therapeutics, Inc. (KRTX) financial statements (2022 and earlier)

Company profile

Business Address 99 HIGH STREET
BOSTON, MA 02110
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:206,95353,048389,400
Cash and cash equivalents206,95353,048208,929
Short-term investments  180,468
Other undisclosed cash, cash equivalents, and short-term investments  3
Receivables1,750  
Prepaid expense1002,116694
Deferred costs455405 
Other current assets7081,088485
Other undisclosed current assets307,368287,9422,127
Total current assets:517,334344,599392,706
Noncurrent Assets
Operating lease, right-of-use asset6,4532,420 
Property, plant and equipment3,092449195
Restricted cash and investments261157 
Other noncurrent assets531  
Other undisclosed noncurrent assets  123
Total noncurrent assets:10,3373,026318
TOTAL ASSETS:527,671347,625393,024
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities18,0386,0092,900
Accounts payable1,939865547
Accrued liabilities16,0995,1442,353
Due to related parties  51
Other undisclosed current liabilities2,1758447
Total current liabilities:20,2136,8532,958
Noncurrent Liabilities
Long-term debt and lease obligation5,3281,841 
Operating lease, liability5,3281,841 
Liabilities, other than long-term debt104  
Other liabilities104  
Other undisclosed noncurrent liabilities (1,841)150
Total noncurrent liabilities:5,4321,841150
Total liabilities:25,6458,6943,108
Stockholders' equity
Stockholders' equity attributable to parent, including:502,026338,931389,916
Common stock333
Additional paid in capital790,391482,955465,420
Accumulated other comprehensive income  5
Accumulated deficit(287,871)(144,066)(75,512)
Other undisclosed stockholders' equity attributable to parent(497)39 
Total stockholders' equity:502,026338,931389,916
TOTAL LIABILITIES AND EQUITY:527,671347,625393,024

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
Revenues36,964  
Gross profit:36,964  
Operating expenses(180,817)(71,816)(45,405)
Operating loss:(143,853)(71,816)(45,405)
Nonoperating income543,3051,448
Investment income, nonoperating5023,3052,517
Loss from continuing operations before income taxes:(143,799)(68,511)(43,957)
Income tax expense(6)(43) 
Net loss available to common stockholders, diluted:(143,805)(68,554)(43,957)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
Net loss:(143,805)(68,554)(43,957)
Comprehensive loss:(143,805)(68,554)(43,957)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(536)345
Comprehensive loss, net of tax, attributable to parent:(144,341)(68,520)(43,952)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: